2022年度肾细胞癌基础研究及临床诊疗新进展

doi:10.19401/j.cnki.1007-3639.2023.03.001

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (3): 191-200.doi: 10.19401/j.cnki.1007-3639.2023.03.001

2022年度肾细胞癌基础研究及临床诊疗新进展

田熙(), 徐文浩, 朱殊璇, 艾合太木江·安外尔, 宿佳琦, 叶世琪, 瞿元元, 施国海, 张海梁, 叶定伟()

复旦大学附属肿瘤医院泌尿外科，复旦大学上海医学院肿瘤学系，上海 200032

收稿日期:2023-01-30 修回日期:2023-02-28 出版日期:2023-03-30 发布日期:2023-04-17
通信作者: 叶定伟（ORCID: 0000-0002-0836-391X），博士，主任医师，复旦大学附属肿瘤医院党委副书记、泌尿外科学科带头人。
作者简介:田熙（ORCID: 0000-0003-1965-0647），博士在读。
叶定伟，教授，复旦大学附属肿瘤医院党委副书记，复旦大学附属肿瘤医院泌尿外科学科带头人、泌尿肿瘤多学科团队首席专家，上海市泌尿肿瘤研究所所长，复旦大学前列腺肿瘤研究所所长。担任中国抗癌协会男性生殖系统肿瘤专业委员会主任委员，中国临床肿瘤学会前列腺癌专家委员会主任委员，中国初级卫生保健基金会泌尿外科专业委员会主任委员，中国抗癌协会泌尿系统肿瘤专业委员会前任主任委员，中华医学会泌尿外科学分会肿瘤学组副组长兼中国前列腺癌研究协作组主任委员，中国临床肿瘤学会尿路上皮癌专家委员会副主任委员，中国临床肿瘤学会肾癌专家委员会副主任委员，中国临床肿瘤学会免疫治疗专家委员会副主任委员，上海市抗癌协会泌尿肿瘤专业委员会主任委员，美国国立综合癌症网络肾癌诊治指南中国版编写组副组长，美国国立综合癌症网络前列腺癌、肾癌和膀胱癌亚洲诊治共识专家委员会委员，晚期前列腺癌圣加仑共识专家委员会委员，亚太前列腺癌学会候任主任委员，亚太冷冻外科学会副会长。Asian Journal of Andrology副主编，Prostate Cancer and Prostatic Disease、British Journal of Urology International编委。擅长泌尿男生殖系统肿瘤的手术和综合治疗，每年主刀根治手术近千台。主持国家级、省部级科研基金60余项。以第一作者或通信作者发表论文676篇，其中在SCI收录期刊上发表402篇，包括Nature Genetics、Journal of Clinical Oncology、European Urology、Clinical Cancer Research、Cell Research等。主编、主译专著9本，发明和实用新型专利32项。牵头国际、国内多中心临床试验和研究84项。以第一完成人获上海市科技进步奖一等奖2项，教育部科技成果一等奖、二等奖各1项，上海市医学科技奖一等奖1项，中华医学科技奖二等奖和中国抗癌协会科技奖二等奖各1项，以第三完成人获国家科技进步一等奖1项。此外，还获得吴阶平泌尿外科医学奖、药明康德生命化学研究奖。获国家卫生健康委员会有突出贡献中青年专家、上海工匠、全国卫生计生系统先进工作者、上海市领军人才、上海市医学领军人才、上海市优秀学科带头人等荣誉称号，享受国务院政府特殊津贴。
基金资助:
国家自然科学基金(82172817);上海市“科技创新行动计划”医学创新研究专项(22Y11905100);上海市“科技创新行动计划”启明星项目（A类）(23QA1408900)

Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022

TIAN Xi(), XU Wenhao, ZHU Shuxuan, AIHETAIMUJIANG•Anwaier, SU Jiaqi, YE Shiqi, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei()

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2023-01-30 Revised:2023-02-28 Published:2023-03-30 Online:2023-04-17
Contact: YE Dingwei

摘要/Abstract

摘要：

肾细胞癌（renal cell carcinoma，RCC）是泌尿系统三大肿瘤之一，随着生活方式的改变以及肥胖、高血压等系统疾病的增多，中国的RCC发病率也呈逐年上升趋势。RCC起病隐匿，大多数RCC患者是通过影像学检查偶然发现的，不少患者确诊时已是晚期。虽然靶向治疗和免疫治疗的出现显著延长了晚期RCC患者的生存时间，但RCC病理学类型众多，许多RCC患者仍难以从系统性治疗中获益。大量基础和临床研究致力于探索新的靶点及治疗药物，以进一步改善患者的预后。本文总结2022年度RCC研究和诊疗新进展，旨在为临床诊治提供新思路。

关键词: 肾细胞癌, 免疫治疗, 靶向治疗, 基础研究, 临床研究

Abstract:

Renal cell carcinoma (RCC) is one of the three major urinary system tumors. With the changes of lifestyle and the rise of obesity, hypertension and other diseases, the incidence of RCC is increasing. The onset of RCC is hidden, and RCC has strong heterogeneity. Most RCC patients are found accidentally by imaging examination, so many patients were diagnosed in the advanced stage. Although the emergence of targeted therapy and immunotherapy has greatly prolonged the survival time of patients with advanced RCC, due to many pathological types of RCC, it is still difficult for many patients to benefit from the systematic treatment. Many basic and clinical studies are devoted to the development of new targets or drugs to prolong the survival time of patients. This article reviewed the advances in the research, diagnosis and treatment of RCC in 2022.

Key words: Renal cell carcinoma, Immunotherapy, Targeted therapy, Basic research, Clinical research

中图分类号:

R737.11

田熙, 徐文浩, 朱殊璇, 艾合太木江·安外尔, 宿佳琦, 叶世琪, 瞿元元, 施国海, 张海梁, 叶定伟. 2022年度肾细胞癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 191-200.

TIAN Xi, XU Wenhao, ZHU Shuxuan, AIHETAIMUJIANG•Anwaier, SU Jiaqi, YE Shiqi, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022[J]. China Oncology, 2023, 33(3): 191-200.

参考文献 67

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.v71.3
[2]	MOCH H, CUBILLA A L, HUMPHREY P A, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70(1): 93-105. doi: S0302-2838(16)00206-2 pmid: 26935559
[3]	THORSTENSON A, BERGMAN M, SCHERMAN-PLOGELL A H, et al. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register[J]. Scand J Urol, 2014, 48(3): 231-238. doi: 10.3109/21681805.2013.864698 pmid: 24666102
[4]	BUKAVINA L, BENSALAH K, BRAY F, et al. Epidemiology of renal cell carcinoma: 2022 update[J]. Eur Urol, 2022, 82(5): 529-542. doi: 10.1016/j.eururo.2022.08.019 pmid: 36100483
[5]	ROGER V L, GO A S, LLOYD-JONES D M, et al. Heart disease and stroke statistics: 2011 update: a report from the American Heart Association[J]. Circulation, 2011, 123(4): e18-e209.
[6]	LIU X Q, PEVERI G, BOSETTI C, et al. Dose-response relationships between cigarette smoking and kidney cancer: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2019, 142: 86-93. doi: S1040-8428(19)30163-5 pmid: 31387065
[7]	EHDAIE B, FURBERG H, ZABOR E C, et al. Comprehensive assessment of the impact of cigarette smoking on survival of clear cell kidney cancer[J]. J Urol, 2014, 191(3): 597-602. doi: 10.1016/j.juro.2013.08.081 pmid: 24018238
[8]	BHASKARAN K, DOUGLAS I, FORBES H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults[J]. Lancet, 2014, 384(9945): 755-765. doi: 10.1016/S0140-6736(14)60892-8
[9]	CHOI Y, PARK B, JEONG B C, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis[J]. Int J Cancer, 2013, 132(3): 625-634. doi: 10.1002/ijc.27639 pmid: 22610826
[10]	KAELIN W G JR. The VHL tumor suppressor gene: insights into oxygen sensing and cancer[J]. Trans Am Clin Climatol Assoc, 2017, 128: 298-307. pmid: 28790514
[11]	AL-BAYATI O, HASAN A, PRUTHI D, et al. Systematic review of modifiable risk factors for kidney cancer[J]. Urol Oncol, 2019, 37(6): 359-371. doi: 10.1016/j.urolonc.2018.12.008
[12]	HIDAYAT K, DU X, ZOU S Y, et al. Blood pressure and kidney cancer risk: meta-analysis of prospective studies[J]. J Hypertens, 2017, 35(7): 1333-1344. doi: 10.1097/HJH.0000000000001286 pmid: 28157813
[13]	LEE J E, HUNTER D J, SPIEGELMAN D, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies[J]. J Natl Cancer Inst, 2007, 99(10): 801-810. doi: 10.1093/jnci/djk181 pmid: 17505075
[14]	BAGNARDI V, ROTA M, BOTTERI E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis[J]. Br J Cancer, 2015, 112(3): 580-593. doi: 10.1038/bjc.2014.579
[15]	QU Y Y, FENG J W, WU X H, et al. A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population[J]. Nat Commun, 2022, 13(1): 2052. doi: 10.1038/s41467-022-29577-x pmid: 35440542
[16]	LI Y, LIH T M, DHANASEKARAN S M, et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness[J]. Cancer Cell, 2023, 41(1): 139-163.e17. doi: 10.1016/j.ccell.2022.12.001 pmid: 36563681
[17]	LI R Y, FERDINAND J R, LOUDON K W, et al. Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer[J]. Cancer Cell, 2022, 40(12): 1583-1599.e10. doi: 10.1016/j.ccell.2022.11.001 pmid: 36423636
[18]	BÜTTNER F A, WINTER S, STÜHLER V, et al. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy[J]. Genome Med, 2022, 14(1): 105. doi: 10.1186/s13073-022-01105-y pmid: 36109798
[19]	PATEL S A, HIROSUE S, RODRIGUES P, et al. The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer[J]. Nature, 2022, 606(7916): 999-1006. doi: 10.1038/s41586-022-04809-8
[20]	ZHOU J, SIMON J M, LIAO C, et al. An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma[J]. Mol Cell, 2022, 82(16): 3030-3044. e8. doi: 10.1016/j.molcel.2022.06.003 pmid: 35764091
[21]	XIE Y C, SAHIN M, SINHA S, et al. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes[J]. Nat Cancer, 2022, 3(2): 188-202. doi: 10.1038/s43018-021-00316-3
[22]	BOOTSMA M, MCKAY R R, EMAMEKHOO H, et al. Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma[J]. J Clin Oncol, 2022, 40(31): 3633-3641. doi: 10.1200/JCO.22.00219
[23]	HAGIWARA M, FUSHIMI A, MATSUMOTO K, et al. The significance of PARP1 as a biomarker for predicting the response to PD-L1 blockade in patients with PBRM1-mutated clear cell renal cell carcinoma[J]. Eur Urol, 2022, 81(2): 145-148. doi: 10.1016/j.eururo.2021.09.024
[24]	GOLKARAM M, KUO F S, GUPTA S, et al. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape[J]. Genome Med, 2022, 14(1): 143. doi: 10.1186/s13073-022-01146-3 pmid: 36536472
[25]	QU Y Y, WU X H, ANWAIER A, et al. Proteogenomic characterization of MiT family translocation renal cell carcinoma[J]. Nat Commun, 2022, 13(1): 7494. doi: 10.1038/s41467-022-34460-w pmid: 36470859
[26]	WANG Q, ZHANG Y, ZHANG B L, et al. Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma[J]. Nat Commun, 2022, 13(1): 31. doi: 10.1038/s41467-021-27660-3 pmid: 35013217
[27]	GE X, LI M D, YIN J X, et al. Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma[J]. Mol Cell, 2022, 82(7): 1249-1260.e7. doi: 10.1016/j.molcel.2022.01.029 pmid: 35216667
[28]	SUN R, BREAU R H, MALLICK R, et al. Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: results from Canadian kidney cancer information system[J]. Can Urol Assoc J, 2021, 15(4): 132-137.
[29]	VASUDEV N S, WILSON M, STEWART G D, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer[J]. BMJ Open, 2020, 10(5): e035938.
[30]	VOGEL C, ZIEGELMÜLLER B, LJUNGBERG B, et al. Imaging in suspected renal-cell carcinoma: systematic review[J]. Clin Genitourin Cancer, 2019, 17(2): e345-e355. doi: 10.1016/j.clgc.2018.07.024
[31]	ROSSI S H, PREZZI D, KELLY-MORLAND C, et al. Imaging for the diagnosis and response assessment of renal tumours[J]. World J Urol, 2018, 36(12): 1927-1942. doi: 10.1007/s00345-018-2342-3 pmid: 29948048
[32]	MA H, SHEN G H, LIU B, et al. Diagnostic performance of ¹⁸F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis[J]. Nucl Med Commun, 2017, 38(2): 156-163. doi: 10.1097/MNM.0000000000000618
[33]	VOSS J, DRAKE T, MATTHEWS H, et al. Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort[J]. BJU Int, 2020, 125(4): 561-567. doi: 10.1111/bju.15001 pmid: 31955483
[34]	KOTECHA R R, FLIPPOT R, NORTMAN T, et al. Prognosis of incidental brain metastases in patients with advanced renal cell carcinoma[J]. J Natl Compr Canc Netw, 2021, 19(4): 432-438. doi: 10.6004/jnccn.2020.7634
[35]	SILVERMAN S G, PEDROSA I, ELLIS J H, et al. Bosniak classification of cystic renal masses, version 2019: an update proposal and needs assessment[J]. Radiology, 2019, 292(2): 475-488. doi: 10.1148/radiol.2019182646 pmid: 31210616
[36]	CHANDRASEKAR T, AHMAD A E, FADAAK K, et al. Natural history of complex renal cysts: clinical evidence supporting active surveillance[J]. J Urol, 2018, 199(3): 633-640. doi: S0022-5347(17)77564-7 pmid: 28941915
[37]	LJUNGBERG B, ALBIGES L, ABU-GHANEM Y, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update[J]. Eur Urol, 2022, 82(4): 399-410. doi: 10.1016/j.eururo.2022.03.006 pmid: 35346519
[38]	LEVERIDGE M J, FINELLI A, KACHURA J R, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy[J]. Eur Urol, 2011, 60(3): 578-584. doi: 10.1016/j.eururo.2011.06.021 pmid: 21704449
[39]	MOCH H, AMIN M B, BERNEY D M, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours[J]. Eur Urol, 2022, 82(5): 458-468. doi: 10.1016/j.eururo.2022.06.016 pmid: 35853783
[40]	JIA L, CARLO M I, KHAN H, et al. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases[J]. Mod Pathol, 2019, 32(9): 1329-1343. doi: 10.1038/s41379-019-0273-1
[41]	COLOMBO P, SMITH S C, MASSA S, et al. Unclassified renal cell carcinoma with medullary phenotype versus renal medullary carcinoma: lessons from diagnosis in an Italian man found to harbor sickle cell trait[J]. Urol Case Rep, 2015, 3(6): 215-218. doi: 10.1016/j.eucr.2015.07.011 pmid: 26793557
[42]	YU L, LI J, XU S P, et al. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report[J]. Diagn Pathol, 2016, 11(1): 98. pmid: 27733182
[43]	KRYVENKO O N. Tumor necrosis adds prognostically significant information to grade in clear cell renal cell carcinoma: a study of 842 consecutive cases from a single institution[J]. Urol Oncol, 2017, 35(6): 454-455. doi: 10.1016/j.urolonc.2017.03.023
[44]	SUKOV W R, HODGE J C, LOHSE C M, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients[J]. Mod Pathol, 2012, 25(11): 1516-1525. doi: 10.1038/modpathol.2012.107
[45]	TAO J J, WEI G, PATEL R, et al. ALK fusions in renal cell carcinoma: response to entrectinib[J]. JCO Precis Oncol, 2018, 2: 1-8. doi: 10.1200/PO.18.00185 pmid: 35135161
[46]	SHAH R B, STOHR B A, TU Z J, et al. Renal cell carcinoma with leiomyomatous stroma harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity[J]. Am J Surg Pathol, 2020, 44(5): 571-581. doi: 10.1097/PAS.0000000000001422
[47]	SMITH S C, SIROHI D, OHE C, et al. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma[J]. Histopathology, 2017, 71(1): 42-52. doi: 10.1111/his.13183 pmid: 28165631
[48]	WYVEKENS N, VALTCHEVA N, MISCHO A, et al. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach[J]. Genes Chromosom Cancer, 2020, 59(11): 611-619. doi: 10.1002/gcc.v59.11
[49]	PALSGROVE D N, LI Y J, PRATILAS C A, et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum[J]. Am J Surg Pathol, 2018, 42(9): 1166-1181. doi: 10.1097/PAS.0000000000001111 pmid: 29975249
[50]	TRPKOV K, ABOU-OUF H, HES O, et al. Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity[J]. Am J Surg Pathol, 2017, 41(10): 1299-1308. doi: 10.1097/PAS.0000000000000838 pmid: 28786877
[51]	MACLENNAN S, IMAMURA M, LAPITAN M C, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer[J]. Eur Urol, 2012, 61(5): 972-993. doi: 10.1016/j.eururo.2012.02.039 pmid: 22405593
[52]	CAPITANIO U, TERRONE C, ANTONELLI A, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T_1a-T_1b renal mass and normal preoperative renal function[J]. Eur Urol, 2015, 67(4): 683-689. doi: 10.1016/j.eururo.2014.09.027
[53]	ALAM R, PATEL H D, OSUMAH T, et al. Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study[J]. BJU Int, 2019, 123(1): 42-50. doi: 10.1111/bju.14490 pmid: 30019484
[54]	SPRENKLE P C, POWER N, GHONEIM T, et al. Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters[J]. Eur Urol, 2012, 61(3): 593-599. doi: 10.1016/j.eururo.2011.11.040 pmid: 22154728
[55]	BAKOUNY Z, EL ZARIF T, DUDANI S, et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium[J]. Eur Urol, 2023, 83(2): 145-151. doi: 10.1016/j.eururo.2022.10.004
[56]	MOTZER R, ALEKSEEV B, RHA S Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300. doi: 10.1056/NEJMoa2035716
[57]	RINI B I, PLIMACK E R, STUS V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1116-1127. doi: 10.1056/NEJMoa1816714
[58]	CHOUEIRI T K, POWLES T, BUROTTO M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2021, 384(9): 829-841. doi: 10.1056/NEJMoa2026982
[59]	CHOUEIRI T K, POWLES T B, ALBIGES L, et al. LBA8-phase Ⅲ study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)[J]. Ann Oncol, 2022, 33(suppl_7): S808-S869.
[60]	JONASCH E, MICHAEL BAUER T, PAPADOPOULOS K P, et al. Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up[J]. J Clin Oncol, 2022, 40(suppl 16): Abstr 4509.
[61]	MCDERMOTT D F, CHOUEIRI T K, TYKODI S, et al. 1453P-phase Ⅱ study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): update from cohort 2 of LITESPARK-003[J]. Ann Oncol, 2022, 33(suppl_7): S660-S680.
[62]	DIZMAN N, MEZA L, BERGEROT P, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial[J]. Nat Med, 2022, 28(4): 704-712. doi: 10.1038/s41591-022-01694-6 pmid: 35228755
[63]	DIAB A, GOGAS H J, SANDHU S K, et al. 785O-PIVOT IO 001: first disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)[J]. Ann Oncol, 2022, 33 (suppl_7): S356-S409.
[64]	ARMSTRONG A J, HALABI S, EISEN T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial[J]. Lancet Oncol, 2016, 17(3): 378-388. doi: S1470-2045(15)00515-X pmid: 26794930
[65]	PAL S K, TANGEN C, THOMPSON I M JR, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet, 2021, 397(10275): 695-703. doi: 10.1016/S0140-6736(21)00152-5 pmid: 33592176
[66]	LEE C H, VOSS M H, CARLO M I, et al. Phase Ⅱ trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates[J]. J Clin Oncol, 2022, 40(21): 2333-2341. doi: 10.1200/JCO.21.01944
[67]	LEE C H, SHAH A Y, RASCO D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (study 111/KEYNOTE-146): a phase 1b/2 study[J]. Lancet Oncol, 2021, 22(7): 946-958. doi: 10.1016/S1470-2045(21)00241-2

2022年度肾细胞癌基础研究及临床诊疗新进展

Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 67

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑盛锋, 朱一平, 叶定伟. 2022年度膀胱癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 201-209.
[2]	潘剑, 朱耀, 戴波, 叶定伟. 2022年度前列腺癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 210-217.
[3]	苏春霞, 周彩存. 2022年度肺癌领域重要临床研究进展[J]. 中国癌症杂志, 2023, 33(3): 218-227.
[4]	曾铖, 张剑. 2022年度ADC在胰腺癌领域的研究新进展及展望[J]. 中国癌症杂志, 2023, 33(3): 235-240.
[5]	曹晓珊, 丛斌斌. 三阳性乳腺癌内分泌治疗联合靶向治疗的研究进展[J]. 中国癌症杂志, 2023, 33(3): 288-292.
[6]	邵志博, 杨犇龙, 吴炅. 2022年中国乳腺癌重要临床试验成果及最新进展[J]. 中国癌症杂志, 2023, 33(2): 103-109.
[7]	张会强, 江泽飞. 2022年改变晚期乳腺癌临床实践的重要研究[J]. 中国癌症杂志, 2023, 33(2): 110-116.
[8]	郭晴, 张剑. HER2低表达乳腺癌的靶向治疗研究进展[J]. 中国癌症杂志, 2023, 33(2): 181-190.
[9]	王旭, 程合, 刘辰, 虞先濬. 2022年度胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2023, 33(1): 1-13.
[10]	陈瑛瑶, 储香玲, 俞昕, 苏春霞. 免疫检查点抑制剂疗效相关预测模型的研究进展[J]. 中国癌症杂志, 2023, 33(1): 61-70.
[11]	肖玉铃, 朱秀之, 江一舟, 邵志敏. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679.
[12]	周文斌, 谢晖, 丁强, 王水. 在乳腺癌局部精准治疗中的新进展：联合免疫治疗未来可期[J]. 中国癌症杂志, 2022, 32(8): 698-704.
[13]	苏春霞, 周彩存. 晚期非小细胞肺癌免疫治疗现状及未来方向[J]. 中国癌症杂志, 2022, 32(6): 478-486.
[14]	虞思来, 倪建佼, 朱正飞. 免疫治疗时代不可手术局部晚期非小细胞肺癌的治疗：现状与展望[J]. 中国癌症杂志, 2022, 32(6): 487-498.
[15]	李小秋, CD30阳性淋巴瘤病理专家组. CD30在淋巴瘤中的表达及检测：现状与挑战[J]. 中国癌症杂志, 2022, 32(6): 512-518.